Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Castration Resistant Prostate Cancer (TheraPb - Phase I/II Study).
Phase 1
Recruiting
- Conditions
- Prostate CancerMetastatic Castration-resistant Prostate Cancer
- Interventions
- Drug: [²¹²Pb]Pb-ADVC001
- First Posted Date
- 2023-02-09
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- AdvanCell Isotopes Pty Limited
- Target Recruit Count
- 100
- Registration Number
- NCT05720130
- Locations
- 🇦🇺
Princess Alexandra Hospital, Brisbane, Queensland, Australia
🇦🇺Royal Brisbane & Women's Hospital, Brisbane, Queensland, Australia
© Copyright 2025. All Rights Reserved by MedPath